Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

As most readers may be aware (and as I covered in my last note), Novavax, with the help of $1.6bn funding from the U.S. government in 2020, created a COVID vaccine, Nuvaxovid, which was as ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

The Department of Health and Human Services under Robert F. During his Senate confirmation hearings, Health Secretary Robert ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against ...

Novavax, Inc. (Nasdaq: NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV ...

The Subject Expert Committee (SEC) under the COVID-19 division of the Central Drugs Standard Control Organization (CDSCO) has ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

Novavax vaccines could be available soon after Labor Day, the company said. The Biden administration also plans to restart its free covid-test-by-mail program in late September, allowing Americans ...